Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus

As a clinical setting in which local live biological therapy is already well established, non-muscle invasive bladder cancer (NMIBC) presents intriguing opportunities for oncolytic virotherapy. Coxsackievirus A21 (CVA21) is a novel intercellular adhesion molecule-1 (ICAM-1)-targeted immunotherapeuti...

Full description

Bibliographic Details
Main Authors: Nicola E. Annels, Mehreen Arif, Guy R. Simpson, Mick Denyer, Carla Moller-Levet, David Mansfield, Rachel Butler, Darren Shafren, Gough Au, Margaret Knowles, Kevin Harrington, Richard Vile, Alan Melcher, Hardev Pandha
Format: Article
Language:English
Published: Elsevier 2018-06-01
Series:Molecular Therapy: Oncolytics
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770518300044

Internet

http://www.sciencedirect.com/science/article/pii/S2372770518300044

Similar Items